0001104659-19-021850.txt : 20190417 0001104659-19-021850.hdr.sgml : 20190417 20190417093550 ACCESSION NUMBER: 0001104659-19-021850 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190417 FILED AS OF DATE: 20190417 DATE AS OF CHANGE: 20190417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Danilkovitch Alla CENTRAL INDEX KEY: 0001636236 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32966 FILM NUMBER: 19752332 MAIL ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE STREET 2: OSIRIS THERAPEUTICS, INC. CITY: COLUMBIA STATE: MD ZIP: 21046 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001360886 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 710881115 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 443-545-1819 MAIL ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 4 1 a4.xml 4 X0306 4 2019-04-17 1 0001360886 OSIRIS THERAPEUTICS, INC. OSIR 0001636236 Danilkovitch Alla C/O OSIRIS THERAPEUTICS, INC. 7075 ALBERT EINSTEIN DRIVE COLUMBIA MD 21046 0 1 0 0 Chief Scientific Officer Common Stock 2019-04-17 4 D 0 9375 19.00 D 0 D Incentive Stock Option (right to buy) 7.74 2019-04-17 4 D 0 8000 0 D 2020-03-12 Common Stock 8000 0 D Incentive Stock Option (right to buy) 6.46 2019-04-17 4 D 0 5000 0 D 2020-05-27 Common Stock 5000 0 D Incentive Stock Option (right to buy) 7.13 2019-04-17 4 D 0 9000 0 D 2021-02-14 Common Stock 9000 0 D Incentive Stock Option (right to buy) 5.08 2019-04-17 4 D 0 6000 0 D 2022-03-23 Common Stock 6000 0 D Incentive Stock Option (right to buy) 7.73 2019-04-17 4 D 0 10000 0 D 2023-02-12 Common Stock 10000 0 D Non-Qualified Stock Option (right to buy) 14.00 2019-04-17 4 D 0 1436 0 D 2024-05-06 Common Stock 1436 0 D Incentive Stock Option (right to buy) 14.00 2019-04-17 4 D 0 18564 0 D 2024-05-06 Common Stock 18564 0 D Incentive Stock Option (right to buy) 18.40 2019-04-17 4 D 0 7644 0 D 2025-03-06 Common Stock 7644 0 D Non-Qualified Stock Option (right to buy) 18.40 2019-04-17 4 D 0 17356 0 D 2025-03-06 Common Stock 17356 0 D Non-Qualified Stock Option (right to buy) 6.80 2019-04-17 4 D 0 24997 0 D 2027-07-19 Common Stock 24997 0 D Incentive Stock Option (right to buy) 6.80 2019-04-17 4 D 0 25003 0 D 2027-07-19 Common Stock 25003 0 D On March 12, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Smith & Nephew Consolidated, Inc., a Delaware corporation ("Parent"), Papyrus Acquisition Corp., a Maryland corporation and a direct subsidiary of Parent ("Purchaser") and Smith & Nephew plc, an English public limited company. Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired at a purchase price of $19.00 per share (the "Offer Price") in cash. Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal to the excess, if any, of (A) the Offer Price over (B) the exercise price per share of such stock option, multiplied by the number of shares of Common Stock subject to such option. /s/ Alla Danilkovitch 2019-04-17